Reed Jobs runs Yosemite, a biotech-focused venture firm that has grown substantially since its 2021 launch. The firm now operates with 17 team members and has positioned itself at the intersection of drug development and artificial intelligence.
Jobs founded Yosemite during a difficult period for biotech investment, when the sector was recovering from pandemic-related funding declines. The timing proved advantageous. A wave of major pharmaceutical patents expire within the same window, creating opportunities for generic drug manufacturers, biosimilar producers, and developers of next-generation treatments. This patent cliff removes barriers to entry for new players challenging incumbents.
AI has become central to Yosemite's strategy. Where the technology once seemed peripheral to biotech, it now accelerates drug discovery, protein folding analysis, and clinical trial design. Jobs credits AI with enabling faster deal evaluation and portfolio company support across his investments.
The firm's growth trajectory surprised even Jobs himself. In three years, Yosemite moved from launch mode to managing a meaningful portfolio with institutional backing and deal flow. The venture capitalist emphasizes disease research and therapeutic breakthroughs over his family name, though his connection to Apple co-founder Steve Jobs inevitably shapes how media covers his work.
Yosemite operates in a crowded biotech VC landscape where firms like Andreessen Horowitz's biosector team, Flagship Pioneering, and Khosla Ventures compete for deal access. Jobs differentiates through technical depth, AI integration, and conviction on near-term pharma transitions. The firm backs companies targeting both well-characterized diseases where patent cliffs create openings and novel therapeutic approaches where AI unlocks previously intractable problems.
Jobs's comments suggest confidence in the sector's rebound. Biotech VC funding has recovered from pandemic lows, and the convergence of expiring patents